Cerevance – a company focused on novel therapeutics for neurological and psychiatric disorders – has launched with operations in the US and the UK, after securing investment from Takeda Pharmaceutical Co. Ltd. and Lightstone Ventures. Takeda has granted the startup its recently shuttered Cambridge, UK laboratory site to progress several preclinical and early stage assets targeting central nervous system (CNS) indications.
Cerevance, which is based on technology created in the Howard Hughes Medical Institute laboratory of Dr Nathaniel Heintz at the...








